The regulation of lysyl oxidase by bFGF and TGF-B1 in osteoblastic MC3T3-E1 Cells by Feres-Filho, Eduardo Jorge
Boston University
OpenBU http://open.bu.edu
Goldman School of Dental Medicine GSDM: Historical Theses and Dissertations (Open Access)
1995
The regulation of lysyl oxidase by





GOLDMAN SCHOOL OF GRADUATE DENTISTRY 
DISSERTATION 
THE REGULATION OF LYSYL OXIDASE BY bFGF AND TGF-JH 
IN OSTEOBLASTIC MCJTJ-El CELLS 
by 
EDUARDO JORGE FERES FILHO, D.D.S., M.S~D. 
Federal University of Rio de Janeiro (UFRJ) 
School of Dentistry 
Rio de Janeiro, Brazil, 1978, 1991 
Submitted in partial fulfillment of the requirements for the degree of 
Doctor of Science in Oral Biology 
1995 
Boston University 
Copyright and Digitization Notice 
 
Copyright of this work is held by the author. 
This work is protected against unauthorized copying under Title 17, United States code. 
This reproduction is made available for personal use, and is not for distribution.  
 
The image quality of this digital reproduction depends on the quality of the print original. Signatures and 





Lysyl oxidase catalyzes the enzymatic step that is limiting for collagen and 
elastin crosslinking. As a crosslinked collagenous extracellular matrix is required for 
bone formation, mineralization and structural integrity, regulation of lysyl oxidase in 
osteoblastic cells, although not previously studied, is likely to have relevance to bone 
synthesis and repair. The goals of this study were to determine whether lysyl oxidase, 
like its type I collagen substrate, is regulated by basic fibroblast growth factor (bFGF) 
and·transforming growth factor beta-1 (TGF-Pl) in osteoblastic MC3T3-El cells. We 
also established the degree of posttranscriptional control by bFGF. Steady-state lysyl 
oxidase mRNA levels were decreased to 30% of control after 24 hours of treatment 
with 1 nM and 10 nM bFGF. This regulation was time-dependent. Similarly, the 
COLlAl mRNA level decreased to less than 10% of control after 24 hours of 
treatment. Media lysyl oxidase activity decreased in accordance with the steady-state 
mRNA changes in bFGF-treated cultures that were refed after 24 hours of growth 
factor treatment. Treatment ofMC3T3-El cells with 0.01 - 0.1 nMbFGF for 24 hours, 
and treatment with 1 nM bFGF for up to 12 hours resulted in a modest stimulation of 
lysyl oxidase gene expression and enzyme activity. Fifty per cent of the down-
m 
regulation of lysyl oxidase was shown to be posttranscriptional by measuring bFGF-
dependent differences in decay rates of lysyl oxidase mRNA in the presence of 5,6-
dichloro-1 J3-D-ribofuranosylbenzimidazole. New protein synthesis was not required 
for the down-regulation by bFGF, but cycloheximide did increase constitutive lysyl 
oxidase mRNA levels 2.5-fold GAPDH or COLlAl mRNA levels were not affected 
by cycloheximide. TGF-J3 l increased the levels of steady-state lysyl oxidase mRNA, 
proenzyme synthesis and secretion, and enzyme activity in a dose- and time-dependent 
manner. A discrepancy between the synthesis of lysyl oxidase proenzyme and enzyme 
activity indicated that the posttranslational maturation of lysyl oxidase may limit full 
activation of lysyl oxidase enzyme activity. TGF-J3 l-mediated effects <?n steady-state 
lysyl oxidase mRNA levels are greater than the effects on steady-state COLlAl 
mRNA levels, suggesting that lysyl oxidase is a major target for TGF-J3 l in this cell 
culture model. Mechanisms of regulation of lysyl oxidase and the possible role of lysyl 
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INTRODUCTION 
Lysyl oxidase is the extracellular enzyme that catalyzes the oxidative 
deamination of lysine residues in collagen and elastin precursors to form peptidyl a-
aminoadipic-8-semialdehyde. The spontaneous condensation of these resultant 
aldehydes leads to the formation of lysine derived crosslinks found in mature collagen 
and elastin (Kagan & Trackman, 1991). As a crosslinked collagen matrix is required 
for differentiation of osteoblastic cells and for bone mineralization (Franceschi & Iyer 
1992), regulation of lysyl oxidase in osteoblastic cells is likely to have relevance to 
bone physiology. In addition, type I collagen synthesis and accumulation have been 
shown to be uncoupled processes in developing osteoblastic MC3T3-El cells 
(Quarles et al., 1992). These cells accumulate collagen in the extracellular matrix 
when the rate of collagen synthesis is decreasing. This suggests post-translational 
control of collagen assembly into fibrils. Recently, lysyl oxidase-mediated control of 
collagen fibrillogenesis has been described in chick osteoblast cultures treated with the 
lysyl oxidase inhibitor, P-aminopropionitrile (BAPN) (Gerstenfeld et al., 1993). 
Further evidence for the role of lysyl oxidase in bone formation is illustrated by in 
vivo studies where growing chicks and rats fed BAPN develop skeletal deformities 
known as lathyrism (Piez et al., 1961; Selye, 1957). 
Among the growth factors known to exist in high amounts in bone, basic 
fibroblast growth factor (bFGF) and transforming growth factor-Pl (TGF-J31) both 
influence the synthesis of extracellular matrix by osteoblasts (Hauschka et al., 1986; 
Saunders & D'Amore, 1991 ). They also stimulate or inhibit the growth of 
mesenchymal cells in vitro, depending on the cell type and culture conditions. As a 
general rule, bFGF is mitogenic to osteoblastic cells, whereas TGF-J3 l acts to inhibit 
cell proliferation and to stimulate matrix deposition (Graves & Cochran, 1990; 
Kinoshita et al., 1993). The increased matrix results from elevated expression of 
collagen, fibronectin, and proteoglycans (Ignotz & Massague, 1987; Takeuchi et 
al., 1995), and decreased secretion of protease activity (Edwards ; et al., 1987; 
Lund _ et al., 1987). bFGF, on the other hand, induces enzyme systems that lead to 
matrix degradation, including collagenase and plasminogen activator (Gross et al., 
1983; Sato & Rifkin, 1988). 
The objective of this thesis project was to determine the role of lysyl oxidase in 
the growth factor-controlled synthesis and deposition of a collagenous bone matrix. To 
accomplish this we analyzed in the osteoblastic MC3T3-El cell model, the effects of 
bFGF and TGF-J31 on lysyl oxidase and COLlAl gene expression and lysyl oxidase 
enzyme activity. The following working hypotheses were developed: 
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1) Lysyl oxidase is regulated by bFGF similarly to the regulation ofCOLlAl; 
2) Lysyl oxidase activity is regulated by TGF-fH in parallel to the regulation of 
steady-state lysyl oxidase mRNA 
These hypotheses are supported by studies showing that bFGF decreases the 
expression of COLlAl, partially at the transcriptional level in this cell culture model 
(Hurley et al., 1993 ); and that lysyl oxidase mRNA increases almost tenfold after 
treatment ofMC3T3-El cells with TGF-iH (Shibanuma et al., 1993). In addition, the 
synthesis and deposition of type I collagen is controlled by unidentified 
posttranslational mechanisms in bone organ cultures treated with TGF-J31 (Centrella 
et al., 1992). 
Our results demonstrate for the first time that lysyl oxidase activity is subject to 
growth factor-regulation in osteoblastic cells. We found that bFGF decreases the levels 
of lysyl oxidase mRNA and enzyme activity, and that this effect is mediated partially 
by posttranscriptional mechanisms. On the other hand, TGF-J31 was found to increase 
the levels of lysyl oxidase mRNA, proenzyme, and enzyme activity. In addition, a 
discrepancy between proenzyme synthesis and enzyme activity indicates that 
posttranslational steps may limit the full maturation and activation of lysyl oxidase. A 
much greater effect ofTGF-J31 on steady-state lysyl oxidase mRNA than on COLlAl 
3 




1. Lysyl oxidase 
Lysyl oxidase is the extracellular enzyme that catalyzes the conversion of 
peptidyl lysine to peptidyl a-aminoadipic-8-semialdehyde in collagen and elastin 
precursors (Siegel, 1979). These reactive aldehydes then spontaneously condense 
with each other, or with unmodified lysine residues to form inter- or intra-chain 
covalent crosslinkages. This reaction leads to increased insolubilization of 
collagen and elastin fibers and deposition· into the extracellular matrix (Kagan, 
1986). 
The discovery of lysyl oxidase and its cofactors 
Feeding the sweet pea (Lathyrus odoratus) to growing rats has long been 
known to cause a variety of connective tissue defects called lathyrism. Features of 
this experimental condition include hernia, aneurysm and skeletal deformity 
(Geiger et al., 1933). Underlying the disease is a dramatic increase in the amount 
of soluble collagen present in the tissues, resulting from a decreased degree of 
interchain crosslinking (Levene & Gross, 1959). The active lathyrogenic agent was 
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found to be J3-aminopropionitrile (BAPN) derived from the compound J3-(a-
glutamyl)aminopropionitrile, present in the lathyrus pea (Bachhuber et al., 1955; 
McKay et al., 1954). Subsequently, BAPN has been used in inhibition studies to 
identify the enzyme involved in crosslinking. 
Page and Benditt (1966), assayed the inhibition of pig plasma amme 
oxidase by BAPN. This enzyme was thought to closely resemble the oxidase 
functional in collagen and elastin crosslinking. They demonstrated that BAPN was 
a competitive, reversible inhibitor that formed a complex with the active site of 
that amine oxidase (Page & Benditt, 1967a). In a subsequent study, the same 
authors concluded that lathyrogens exert their effects on connective tissues by 
causing an . inhibition of the oxidative deamination required for subsequent 
covalent crosslink formation in collagen and elastin (Page & Benditt, 1967b ). 
In 1968, Pinnell and Martin described a radioactive assay for an enzyme 
extracted from embryonic chick bone that converted peptide-bound lysine to the 
aldehyde, allysine (Pinnell & Martin, 1968). That enzyme, lysyl oxidase, was 
irreversibly inhibited by physiologically active levels of BAPN. Later, in assays 
using [6-3H]lysyl-elastin and [14C]lysyl-collagen substrates, lysyl oxidase was 
found to be distinct from plasma amine oxidases, and to participate directly in the 
production of crosslink in collagen and elastin (Siegel et al., 1970a). Further 
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studies on this enzyme established its requirement for copper for catalytic function 
(Harris et al., 1974; Siegel et al., 1970b). 
Dietary copper deficiency results in connective tissue defects quite similar 
to those seen in BAPN-induced experimental lathyrism (Siegel, 1979). Among 
those, aortic aneurysm and bone fragility have been reported. At the biochemical 
level, both conditions present similarities in decreased bone collagen crosslinking 
and increased solubility of collagen and elastin (Rucker et al., 1975). Lysyl 
oxidase activity and the level of dietary copper were correlated linearly in bone 
and tendon of chicks (Opsahl et al., 1982). In skin of rats deprived of copper,. 
lysyl oxidase activity was found to be one-half to one-third the normal values 
(Romero-Chapman et al., 1991 ). Moreover, lysyl oxidase deficiency in the human 
genetic diseases Menke's syndrome, Ehlers-Danlos subtype IX and cutis laxa is 
thought to be secondary to a primary defect in copper metabolism (Kagan, 1986; 
Royce & Steinmann, 1990). 
In addition to copper, lysyl oxidase also contains a covalently bound 
carbonyl prosthetic group which is essential for catalytic function (Kagan, 1986). 
The presence of a second cofactor with carbonyl reactivity in lysyl oxidase was 
suspected due to the severe defects in connective tissues of animals fed with 
ureides, hydrazines and hydrazides. The lathyrogenic effect of these compounds 
were significantly reversed by treatment with pyridoxal (PL) or pyridoxal 
7 
phosphate (PLP) in vivo or in organ culture (Levene, 1961; Rucker & O'Dell, 
1970), thus implicating PL or PLP as a carbonyl cofactor of lysyl oxidase. More 
recent studies, however, support the identity of the carbonyl cofactor as the 
quinone of a trihydroxyphenylalanine residue, which could act as an electron 
acceptor in lysyl oxidase catalysis (Gacheru . et al., 1989). This cofactor would 
result from a posttranslational modification of a tyrosine residue , as is suspected 
for other amine oxidases (Klinman & Mu, 1994). The positive identification of the 
carbonyl cofactor for lysyl oxidase has not yet been published. 
Biosynthesis, processing, and secretion 
Lysyl oxidase is synthesized as a 50 kDa glycoprotein precursor. In normal 
cells this lysyl oxidase precursor is secreted and then proteolytically processed to 
the mature 32 kDa enzyme (Trackman et al., 1992). Whether the lysyl oxidase 
precursor has enzymatic activity is unknown, but there is a report indicating that a 
45 kDa form of rat lysyl oxidase does have enzymatic activity (Romero-Chapman 
et al., 1991). Several other variants of lysyl oxidase have been identified, but the 
molecular basis of this variation is not understood (Sullivan & Kagan , 1982). 
Consistent with its secretion fate, sequencing of lysyl oxidase cDNA 
identified signal peptide motifs and potential cleavage sites at the N-terminal 
region (Trackman et al., 1990). The presence of an extracellular processing 
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enzyme activity which converts the glycosylated 50 kDa precursor to the 32 kDa 
species was demonstrated (Trackman et al., 1992). In this study, conditioned 
medium of neonatal rat aorta smooth muscle cell cultures, a source of processing 
activity, was incubated with conditioned medium containing [35S]-labeled 
precursor synthesized, but not processed, by a tumorigenic cell line transfected 
with a lysyl oxidase expression vector. 
Recently, the cleavage site of the N-terminal propeptide region of the lysyl 
oxidase precursor has been reported (Cronshaw et al., 1995). Due to the 
similarities of this cleavage site with those of the C-propeptide from procollagen I, 
II, and III (Hojima et al., 1985; Kessler & Adar, 1989; Kessler et al., 1986), these 
authors suggest that procollagen C-peptidase might be involved in processing both 
lysyl oxidase and collagen precursors. 
The cloning of lysyl oxidase cDNA's from rat, human, mouse, and chick 
revealed conservation of its coding region (Hamalainen et al., 1991, Hamalainen et 
al., 1993; Kenyon et al., 1991; Mariani et al., 1992; Trackman et al., 1990; Wu et 
al., 1992), and provided evidence that lysyl oxidase is a single copy gene (Chang 
et al., 1993; Mock et al., 1992; Svinarich et al., 1992). The human lysyl oxidase 
gene has been assigned to the chromosome 5 (Hamalainen et al., 1991 ). 
Furthermore, identification of a RFLP in the human lysyl oxidase genomic DNA 
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should assist in studies connecting this enzyme to heritable autosomal connective 
tissue disorders ( Csiszar et al., 1993 ). 
Multiple lysyl oxidase transcripts were found in all species examined 
except for chick (Wu_ et al., 1992). The multiple rat lysyl oxidase transcripts 
observed on Northern blots are due primarily to differential polyadenylation and to 
multiple sites of transcription initiation (Trackman et al., 1995). However, several 
overlaping cDNA clones that would encode a protein with extensive amino acid 
sequence homology to the entire sequence of the secreted form of lysyl oxidase 
has been reported (Kenyon et al., 1993). Indeed, a new gene with sequence and 
structural similarity to the gene encoding lysyl oxidase has been recently identified 
(Kim et al., 1995). These studies raise the possibility of lysyl oxidase being a 
complex of subunits synthesized from at least two different genes. Moreover, a 
possible subunit for lysyl oxidase would provide the basis for understanding the 
mechanism( s) whereby lysyl oxidase can mediate multiple catalytic functions 
(Kim et al., 1995). 
Biological regulation of lysyl oxidase 
Lysyl oxidase expression in cell culture reaches its maximum when 
proliferation has slowed, coincident with the stage of most active matrix 
production (Gonnerman. et al., 1981; Kagan, 1986). In contrast, lysyl oxidase 
activity in the culture media of proliferating, malignantly transformed human cell 
lines is very low, compared to control fibroblast lines (Kuivaniemi et al., 1986). 
Moreover, the expression of rrg (ras recision gene) transcript in mouse NIH 3T3 
cells is markedly down-regulated when these cells are transformed by c-H-ras 
(Contente et al., 1990). These authors further observed retransformation of 
revertant cells after transfection with an antisense rrg cDNA expression vector 
(Contente et al., 1990). Later, rrg was found to encode lysyl oxidase (Kenyon et 
al., 1991; Mariani et al., 1992). Although the physiological importance of those 
findings has yet to be established, it has been suggested that lysyl oxidase might be 
a useful marker to distinguish between different aspects of reversion and 
transformation (Hajnal et al., 1993 ). 
Lysyl oxidase activity is subject to hormonal control in different tissues, 
which suggests its biological importance. Enzyme activity measured in bone of 
vitamin D-deficient chicks increased twofold compared to that in chicks receiving 
control diets ( Gonnerman et al., 197 6) . Estrogen has been shown to increase lysyl 
oxidase activity in rat skin (Sanada et al., 1978) and mouse cervix (Ozasa et al., 
1981 ). Further, the addition of 10-100 nM levels of testosterone to the medium of 
cultured aortic smooth muscle cells increased cell layer enzyme activity 5.5-fold 
(Bronson et al., 1987). 
11 
The regulation of lysyl oxidase by locally acting gowth factors is limited to 
a few reports. For instance, TGF-P 1 has been shown to induce a significant 
eightfold increase in lysyl oxidase mRNA in mouse osteoblastic cells (Shibanuma. 
et al., 1993). In addition, lysyl oxidase mRNA and enzyme activity increase 1.6-
fold in TGF-Pl-treated rat lung fibroblast cultures (Boak _ et al., 1994). 
2. Growth factors 
Polypeptide hormones have a wide variety of effects on mesenchymal cells. 
They act to stimulate or inhibit mitogenesis, chemotaxis, and/or differentiation. 
Bone is unique because of its abundant mineralized extracellular matrix which 
may sequester growth factors and modulate their biological action through 
complex modes of release and presentation to responding cells (Hauschka et al., 
1986). 
Osteoblastic cells synthesize platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), transforming growth factor-P (TGF-P ), insulin-like 
growth factor (IGF), and selected bone morphogenetic proteins (BMPs ), among 
other growth factors (Canalis et al., 1993). The effect of these growth factors in 
vivo probably reflects the cumulative effect of combinations of growth factors 
(Graves & Cochran, 1990). 
12 
In vitro studies showed that FGF, PDGF, and IGF-1 generally stimulated 
cellular proliferation. Fibroblast growth factor depressed formation of the 
collagenous extracellular matrix, whereas PDGF and IGF-1 stimulated collagen 
synthesis (Centrella & Canalis, 1985). In addition, TGF-JH increased the 
extracellular matrix as a result of elevated expression of collagen, fibronectin, and 
proteoglycans (Ignotz & Massague, 1987; Takeuchi et al., 1995), and decreased 
secretion of protease activity (Edwards et al., 1987; Lund et al., 1987), 
Among those growth factors present in greater amounts in bone, TGF-P 1 
and FGF have been suggested to play a role in mesenchymal development 
(Kimelman & Kirschner, 1987) . These agents have also been implicated in 
fracture repair based on the presence of their mRNA in the callus (Bolander, 
1992). Moreover, bFGF and TGF-P 1 have antagonistic effects in some cell 
systems and either additive or potentiating effects in others (Globus , et al., 1988; 
Saunders & D'Amore, 1991). 
Basic fibroblast growth factor 
Basic fibroblast growth factor belongs to a family of nine polypeptide 
growth regulators identified by their unusual affinity for the glycosaminoglycan 
heparin (Mason, 1994). bFGF was discovered by its ability to induce proliferation 
in mouse fibroblasts (Gospodarowicz, 1974). It was later found to be mitogenic to 
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smooth muscle cells, endothelial cells, chondrocytes, and osteoblasts 
(Gospodarowicz et al., 1979). Like other mitogenic polypeptide hormones, bFGF 
is multifunctional and stimulates diverse cellular events, including angiogenesis, 
differentiation of a variety of neural cell types, and tumorigenesis ( Graves & 
Cochran, 1990; Saunders & D'Amore, 1991). 
Different forms of bFGF have been identified, ranging in molecular weight 
from 16,800 to 25,000. The various sized peptides appear to result from alternative 
translation initiation sites and alternative splicing (Florkiewicz & Sommer, 1989). 
However, no functional differences have been demonstrated for the varied 
molecular weight forms ofbFGF (Saunders & D'Amore, 1991). 
Studies employing cDNA sequencing indicate that bFGF lacks a typical N-
terminal motif required for protein secretion, implying that this molecule is only 
released from the cell when the integrity of the plasma membrane is compromised 
(Abraham et al., 1986). Alternatively, exocytosis has been suggested as a novel 
mechanism for bFGF secretion (Mignatti et al., 1992). 
In the extracellular milieu, bFGF is associated with heparin/heparan sulfate 
proteoglycans, and is activated by proteases or heparin-like molecules released by 
endothelial cells at the site of injury (Bashkin et al., 1989; Saksela & Rifkin, 
1990). These findings indicate that bFGF could be important in wound healing and 
fracture repair . 
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The FGF s are known to exert their effects by binding to high affinity 
receptors on the surface of responsive cells. This is potentiated by low affinity 
binding to heparan sulfate proteoglycan molecules located on the cell surface or in 
the extracellular matrix (Yayon et al., 1991). Moreover, bFGF-induced growth 
promotion has been shown to be down-regulated by overexpres~ion of syndecan, 
a heparan sulfate-containing cell surface molecule (Mali: et al., 1993). 
An alternative mode of action has been proposed for bFGF (Bouche et al., 
1987). In this study, exogenous bFGF was demonstrated to enter the cell 
independently of receptor-binding, and to exert its action directly in the nucleus, 
modulating the transcription of ribosomal genes. Recently, this intranuclear 
mechanism of action has also been demonstrated for aFGF (Wiedlocha et al., 
1994). 
The binding of FGFs to their receptors induces receptor dimerization 
(Ueno et al., 1992), and leads to activation of tyrosine kinase activity and receptor 
autophosphorylation (Mansukhani et al., 1990). Activation of the receptor 
tyrosine kinase also leads to increased tyrosine phosphorylation of a number of 
cellular proteins (Peters et al., 1992). Among those, PLC-y has been shown to be 
directly associated with the receptor, following FGF stimulation (Peters: et al., 
1992). 
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The rational design of agonists and antagonists of FGF actions is an 
important avenue for future research with considerable potential for therapeutic 
use . Agonists of FGF might be useful for accelerating wound healing and 
neovascularization. Antagonists of FGF, on the other hand, might be useful for 
blocking angiogenesis in pathological conditions, such as diabetic retinopathy and 
tumor neovascularization (Johnson & Williams, 1993). 
Transforming growth factor-Pl 
The TGF-P family includes three distinct proteins identified in humans: 
TGF-P 1, TGF-f32, and TGF-f33. TGF-P 1 was initially isolated and sequenced 
from platelets and, like TGF-a, was named for its ability to stimulate growth of 
normal fibroblasts in soft agar (Bennett & Schultz, 1993). 
Transforming growth factor-fl 1 is a weak mitogen for cells derived from 
mesoderm, such as osteoblasts. TGF-P 1 is synthesized by a wide variety of cell 
types including platelets, macrophages, lymphocytes, fibroblasts, and osteoblasts . 
Nearly all cells have TGF-Pl receptors, making this one of the most broadly acting 
growth factors (Bennett & Schultz, 1993). In vivo, the highest levels of TGF-Pl 
are found in platelets and bone (Assoian et al., 1983; Seyedin et al., 1985). 
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TGF-P 1 is a dissulfide-linked homodimeric protein of 25,000 molecular 
weight. Each TGF-P 1 subunit is initially synthesized as an inactive precursor 
molecule that is proteolytically processed to generate a 112 amino-acid fragment 
from the C-terminus of the precursor . However, in many cells the N-terminal 
segment of the precursor molecule remains associated with the TGF-J3 protein, 
forming a latent TGF-P complex (Miyazono et al., 1991 ). 
Activation of latent TGF-J3 occurs in conditions such as the presence of 
plasmin (Lyons et al., 1988), or exposure to low a pH environment (Lawrence et 
al., 1985; Pfeilschifter et al., 1990), which occur during wound healing and bone 
resorption . In this context, two of the most important actions of TOF-J3 l are its 
ability to stimulate chemotaxis of inflammatory cells and synthesis of extracellular 
matrix (Bennett & Schultz, 1993). 
Cells in culture have a variety of responses to TGF-J3 l treatment, 
depending of the cell type, cell density, and the presence of other growth factors. 
In general, the diverse actions of TGF-J3 l appear to be mediated by a common 
mechanism: alterations in accumulation and architecture of the extracellular matrix 
(Saunders & D'Amore, 1991). In mesenchymal cell cultures, TGF-J31 has been 
shown to stimulate the synthesis of collagen, fibronectin, and proteoglycans 
(Shibanuma et al., 1991; Shibata et al., 1993; Takeuchi et al., 1995), decrease the 
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expression of extracellular matrix degrading proteins (Laiho et al., 1986; Lund, et 
al., 1987), and stimulate the synthesis of protease inhibitors (Edwards et al., 1987; 
Laiho et al., 1986), 
There are three TGF-f3 receptors with approximate Mr of 60,000, 80,000, 
and 300,000. It is known that receptors type I and II, with respective Mr of 60,000 
and 80,000, mediate the cellular actions of TGF-f3 (Cheifetz et al., 1987). The 
type ill receptor, termed betaglycan, is a large proteoglycan that can be secreted 
and thus may act as a storage site of TGF-f3 on the cell surface and in the 
extracellular matrix (Andres et al., 1989). 
3. Gene expression in osteoblastic cells 
Osteoblasts are mesenchymal cells responsible for the synthesis of proteins 
in the bone matrix (Wlodarski, 1990). They are derived from at least two types of 
osteoprogenitor cells: committed osteoprogenitor cells, which are present in the 
bone marrow, periosteum, and adjacent to endosteal bone surfaces; and inducible 
osteoprogenitor cells which may be responsible for ectopic ossification (Owen, 
1985). 
The developmental sequence of an osteoblastic cell phenotype has been 
divided into three consecutive phases: proliferation, extracellular matrix 
maturation, and mineralization (Stein. et al., 1990). Full differentiation of these 
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cells may require integration with a mature collagenous extracellular matrix, that 
ultimately leads to an orderly mineralization of bone (Franceschi & Iyer, 1992). If 
deposition of a collagenous matrix by proliferating osteoblastic cells in vitro is 
disrupted, the cells do not enter the next developmental phases of osteoblast 
phenotype (Stein et al., 1990). 
Type I collagen 
Type I collagen, the major secretory product of osteoblasts, composes 90% 
of the organic phase of bone matrix. It consists of two identical al type (I) 
polypeptide chains and one a2 type (I) chain (Prockop _ et al., 1979a; Prockop : et 
al., 1979b ). Production of type I collagen is an early event, taking place during 
proliferation of osteoblast precursor cells . A cell committed to the osteoblastic 
lineage no longer expresses type ill collagen, which is otherwise always co-
expressed with type I in mesenchymal cells (Risteli & Risteli, 1993). 
The production of a functional collagenous matrix requires a number of co-
and post-translational steps that are limited to collagen and a few related proteins 
(Slack et al., 1993 ). These include co-translational modifications of amino acids 
such as proline and lysine, and glycosylation of hydroxylysyl side chains. Post-
translational modifications include the intracellular assembly and secretion of the 
triple helical procollagen molecule, limited proteolytic processing by procollagen 
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proteases, and fiber assembly and covalent crosslinking catalyzed by lysyl oxidase 
(Kivirikko, 1993). 
Type I collagen synthesis and accumulation have been shown to be 
uncoupled processes in murine osteoblastic cell cultures (Quarles et al., 1992; 
Franceschi & Iyer, 1992). These cells accumulate collagen in the extracellular 
matrix when the rate of synthesis is decreasing, which argues in favor of a post-
translational-controlled mechanism of collagen deposition. 
Lysyl oxidase-mediated control of collagen fibrillogenesis has been 
described in cultured osteoblasts from chick embryo calvaria (Gerstenfeld: et al., 
1993). Treatment of these cultures with the lysyl oxidase inhibitor BAPN, caused 
a 50% decrease in collagen accumulation and an 80% loss of collagen from the 
cell layer. 
Type I collagen synthesis and deposition in osteoblastic cells are regulated 
by different hormones and growth factors. For instance, the expression of type I 
procollagen gene is stimulated by TGF-P, IGF, and estrogen (Rodan & Noda, 
1991). In murine cells, response to TGF-P appeared to be mediated through the 
NF-1 (Nuclear Factor 1) binding site in the promoter of the type I procollagen 
gene (Rossi, et al., 1988). However, recent studies have demonstrated that TGF-P 
functions in human lung fibroblasts to activate collagen transcription through 
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TGF-P activating element (TAE) sites by protein complexes independent of NF-1 
(Ritzenthaler et al., 1993). TGF-P 1 also up-regulates type I procollagen gene 
expression by stabilizing the messenger RNA (Penttinen _ et al., 1988). 
Furthermore, TGF-P I -stimulated collagen accumulation in cell layers of primary 
rat calvaria osteoblast cell cultures was partially controlled by unidentified post-
translational steps (Centrella et al., 1992). 
Conversely, parathyroid hormone (PTH), FGF, EGF, and vitamin D3 
suppress expression of type I procollagen genes in osteoblasts (Rodan & Noda, 
1991). The inhibitory effects of bFGF are partially mediated by DNA sequences 
located in the al (I) procollagen promoter (Hurley_ et al., 1993). These authors, 
however, did not exclude the possibility of post-transcriptional effects on collagen 
synthesis mediated by bFGF. 
N oncollagenous proteins 
Noncollagenous proteins made by osteoblastic cells constitute 5 to 10% of 
the organic material of the bone matrix (Rodan & Noda, 1991). Among the cellular 
proteins produced at relatively high levels in osteoblasts, alkaline phosphatase is a 
membrane associate enzyme considered an early marker of osteoblast 
differentiation. Mature osteoblasts also produce osteopontin, osteonectin, and 
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osteocalcin, that are deposited together with type I collagen into the bone matrix 
(Erlebacher _ et al., 1995). 
Alkaline phosphatase 
Alkaline phosphatase (ALP) is a homodimer glycoprotein of approximately 
140,000 Da that is highly conserved in evolution. It is present in virtually all cells 
but is most abundant in bone, calcifying cartilage, kidney, and liver (Rodan & 
Noda, 1991). Although its function in vivo is unknown, ALP is thought to be 
involved in bone formation and calcification (Brixen et al., 1989). The latter 
effect might be due to pyrophosphatase activity of the enzyme (Felix & Fleisch, 
1976). 
In mineralizing murine osteoblastic cell cultures, ALP has been shown to 
increase from low baseline levels, when the cells are undifferentiated, to high 
levels at the stage of matrix calcification (Quarles et al., 1992). It also increases 
40-fold at the stage of nodule mineralization (Collin et al., 1992). 
Bone Gia protein ( osteocalcin) 
Bone Gia protein, also called osteocalcin, is a highly conserved 6,000 Da 
protein. It contains three y-carboxy-glutamic residues that allow it to bind calcium 
with high affinity. Formation of y-carboxy-glutamic residues occurs 
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posttranslationally and is vitamin K-dependent. Osteocalcin is produced 
exclusively by osteoblasts, but is not constitutively released (Price & Williamson, 
1981). During the phase of cell growth, no osteocalcin could be detected in the 
medium of a mineralizing rat osteoblastic cell culture. However, at the point of 
nodule formation the osteocalcin level reached a 3 0-fold increase compared to 
baseline values (Collin et al., 1992). Besides being a marker of osteoblastic 
differentiation, the function of osteocalcin is unknown. 
Matrix Gla protein is another vitamin K-dependent y-carboxy-glutamic 
acid containing protein which was isolated from bone but also found in other 
tissues (Rodan & Noda, 1991 ). 
Osteonectin (SP ARC) 
Osteonectin, also known as secreted protein acidic and rich in cysteine 
(SP ARC), is a 32,000 Da protein that has been purified from bone matrix. It has 
also been shown to bind PDGF-B chains, preventing their association with cell 
surface receptors, and thus inhibiting the biological actions of PDGF-AB and -BB 
(Raines et al., 1992). Although it is synthesized by osteoblasts, osteonectin is also 
produced by skin fibroblasts, tendon cells, and odontoblasts. Its function in vivo is 
unknown. In vitro it binds to collagen and hydroxyapatite and promotes or initiates 
crystal growth (Mundy, 1989). 
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Osteopontin 
Osteopontin, or bone sialoprotein, is another major glycoprotein produced 
by osteoblasts and isolated from bone matrix with an approximated Mr of 44,000 
Da (Rodan & Noda, 1991 ). Its function is not certain, but it contains the Arg-Gly-
Asp sequence present in cell attachment proteins, and it promotes the attachment 
o_f osteoblasts and other cells to plastic dishes (Somerman et al., 1987). 
Other macromolecules 
Proteoglycans exist in small amounts within bone. There are two types of 
bone proteoglycans, I and II, produced by osteoblasts (Mundy, 1989). They have a 
core protein of about 45,000 Da, and may be responsible for the orientation of 
collagen fibrils, filling the gaps in non-mineralized tissues (Zheng: et al., 1992). 
Their exact role in the extracellular matrix is unknown, but their degradation is 
required for bulk phase mineral deposition (Dean. et al., 1994). 
4. Osteoblastic cell models 
The production of the above described proteins by osteoblastic cells, the 
presence of high levels of alkaline phosphatase and the responsiveness to 
parathyroid hormone have been used to characterize osteoblastic cells in culture. 
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The differentiation and modulation of osteoblastic features have been studied in 
various experimental systems. 
Cells isolated from mineralizing tissues have been used to study bone 
metabolism, hormonal response, secondary products, interactions with other cell 
types and with extracellular matrices. The cell cultures more commonly employed 
to study the osteoblastic phenotype and its regulation include primary cultures 
from mouse, calf, and chick calvaria, and human, bovine, and murine trabecular 
bone; osteosarcoma derived cell lines from human (Saos-2; MG-63; HOS TE85; 
U-2 OS), and rats (UMR-106; ROS-17/2); experimental immortalized cell lines 
from rat calvaria (RCT-1; RCT-3; PYMS); nontransformed clonal cell lines from 
neonatal rat calvaria (UMR-201), and from newborn mouse calvaria (MC3T3-El) 
(Rodan & Noda, 1991). 
Primary cultures from calvaria have been studied for many years and have 
helped define the osteoblastic phenotype. The advantages of these systems are: 1) 
a vast body of available information ; 2) they are normal embryonic cells which 
retain, at least for some time, properties associated with the differentiated 
phenotype; and 3) these systems contain representatives of the various cell 
populations present in the calvaria (though probably not represented in the same 
proportion). The disavantages are that cells have to be freshly prepared from the 
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tissue every time, giving rise to experimental variability and limiting the number of 
cells which can be practically obtained (Rodan & Noda, 1991). 
In addition to calvaria cells, cells from human, murine, or bovine trabecular 
bone, derived either by cell outgrowth or enzymatic digestion, have also been 
investigated. These cells have essentially the same advantages and disadvantages 
of calvaria-derived cells (Rodan & Noda, 1991 ). 
Some of the limitations associated with cells in primary cultures were 
overcome by the use of tumor-derived or experimentally immortalized cell lines. 
The major advantage of osteosarcoma-derived cells is the ease with which they 
can be cultured, and the relative phenotypic stability. The disavantages are 
uncertainty regarding their similarity to untransformed cells of the same type, and 
lack of information regarding the lesion which led to transformation (Rodan & 
Noda, 1991). 
Experimental immortalized cells with desired phenotypes have been 
generated from rat calvaria cells transfected with retroviral constructs. These cell 
lines have the same advantages as those of the osteosarcoma-derived clones plus 
the fact that the basis for immortalization is known (Rodan & Noda, 1991). 
Nonmalignant cell lines which posses osteoblastic features were obtained 
by cloning rat or mouse calvaria cells. These cells offer the advantages of being 
normal embryonic cells in addition to being clonal cell lines. However, like the 
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primary cultures, they seem to be subject to phenotypic drift when passaged many 
times in culture (Rodan & Noda, 1991). 
MC3T3-El cell model 
MC3T3-El cells were originally obtained from newborn mouse calvaria 
(Kodama et al., 1981). These cells are amongst the more extensively studied 
nonmalignant osteoblast-like cell models. They have been shown to mature in 
culture and acquire many of the features of the osteoblastic phenotype, including 
proliferation of undifferentiated osteoblast precursor followed by post-mitotic 
expression of a differentiated mineralized osteoblast phenotype (Quarles. et al., 
1992). Thi_s property is shared by HOS TE-85 cells, but not by other osteosarcoma 
or immortalized cell lines (Panagakos et al., 1994; Rodan & Noda, 1991). 
Increases in alkaline phosphatase occur in all cultured osteoblastic cells as 
cell density increases. In MC3T3-El cells this increase is dramatic, suggesting 
changes similar to that occurring during the differentiation of osteoblasts from 
mesenchymal precursor cells (Hiraki, et al., 1991 ). Moreover, mineralization 
parallels the increase in ALP and is accelerated by J3-glycerophosphate and 
ascorbate (Dean et al., 1994; Sudo. et al., 1983). 
Synthesis of type I collagen by osteoblasts requires the presence of ascorbic 
acid (Franceschi, 1992). In MC3T3-El cells, addition of ascorbate to the cultures 
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stimulated type I collagen synthesis followed by induction of mRNA for ALP and 
osteocalcin (Franceschi & Iyer, 1992). The levels of osteopontin were not directly 
affected by ascorbic acid, but were similarly increased after initiation of 
mineralization. 
Evidence associating changes in collagen cross-linking patterns with 
collagenous bone matrix maturation and mineralization in bovine embryos has 
been presented (Otsubo et al., 1992). This study has demonstrated that an increase 
in free aldehyde content, and a decrease in the number of molecular segments 
connected by cross-links, is a direct result of mineralization. This may provide a 
mechanism for enhancing certain mechanical characteristics of the skeleton of a 
mature animal. Moreover, calcified tissues present a high dehydro-
dihydroxylysinonorleucine (DHLNL) I dehydro-hydroxylysinonorleucine (HLNL) 
ratio that is related to a higher degree of lysine residue hydroxylation found in 
bone compared to nonmineralized tissues (Kuboki et al., 1992). In addition, these 
authors point out a lesser degree of conversion of DHLNL to pyridinoline in 
calcifiable collagenous matrix. They speculate that tri-functional cross-links may 
preclude mineralization. This is based on the high levels of tri-functional 
pyridinoline found in uncalcified portion of normal bone, and scarce pyridinoline 
content in the cell-matrix fractions of osteoblastic cultures. 
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Detailed studies on collagen crosslinking have also been carried out in 
MC3T3-El cells. For instance, the characteristic higher content of DHLNL cross-
link to bone collagen is maintained in cultures of these cells. Furthermore, a time 
lag of about a week was found between the maximal accumulation of precursor 
aldehyde and formation of cross-links in MC3T3-El cultures (Kuboki. et al., 
1992). This might suggest some requirements for the transition from precursor to 
cross-link such as minimal extracellular accumulation of collagen and/or presence 
of ideal levels oflysyl oxidase enzyme activity. 
Other osteoblastic properties shared by MC3T3-El cells include 
responsiveness to PTH, vitamin D3, prostaglandins, and growth factors (Hurley et 
al., 1994; Kumegawa et al., 1984; Kurihara et al., 1986; Nakatani et al., 1984). 
Moreover, these cells respond to mechanical strain by altering PGE2 production 
(Ozawa et al., 1990). 
Among the growth factors expressed in MC3T3-El cell cultures, TGF-J31 
and bFGF have been shown to exert pleiotropic effects on these cells. For 
instance, treatment of MC3T3-El cells with bFGF and TGF-J3 induced steady-
state bFGF mRNA and protein levels, indicating that production of bFGF may be 
important as an autocrine and paracrine mediator of bone cell replication, 
differentiation, and function (Hurley et al., 1994 ). 
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bFGF has also been shown to regulate the expression of IGF-I in MC3T3-
El cells by decreasing its mRNA and protein levels, and the mRNA and protein 
levels ofIGF-I binding proteins (Hurley et al., 1995). 
In contrast, TGF-f31 stimulated IGF-I release from MC3T3-El cells, and 
this effect was further enhanced by the consecutive addition of PTH to the TGF-
f31-treated culture medium (Elford & Lamberts, 1990). 
Likewise, the M-CSF activity in the conditioned medium of MC3T3-El 
cells was increased by TGF-f31. The M-CSF activity was also induced by PDGF. 
Furthermore, TGF-f31 induced both PDGF-A and PDGF-B chain mRNA levels in 
these cells, suggesting that PDGF autocrine loop-dependent and loop-independent 
pathways could modulate the M-CSF production stimulated by TGF-f31 (Takaishi 
et al., 1994). 
A wealth of information regarding signal transduction mechanisms and 
regulation of gene expression in these cells is available elsewhere, and is beyond 
the scope of this review. The above findings attest to the complexity of the 
cytokine network modulating osteoblastic cells function. Further, the MC3T3-El 
cell model has been shown to be suitable for the study of the development of a 
mineralized extracellular matrix regulated by different factors. 
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MATERIALS AND METHODS 
Materials. Recombinant human basic fibroblast growth factor (bFGF) was 
purchased from Pepro Tech Inc (Rocky Hill, NJ) . Recombinant human transforming 
growth factor-(31 (TGF-(31) was purchased from Austral Biologicals (San Ramon, 
CA). TRI Reagent™ was obtained from Molecular Research Center, Inc., Cincinnati, 
OH_. Dulbecco's modified Eagle's medium (DMEM), newborn bovine serum (NBS), 
trypsin-EDTA solution, penicillin-streptomycin solution, Dulbecco~s phosphate 
buffered saline (PBS), non-essential amino acids solution, bovine albumin fraction V 
(BSA), ascorbic acid, (3-glycerophosphate 5,6-dichloro-1(3-D-
ribofuranosylbenzimidazole (DRB) and cycloheximide were purchased from Sigma 
Chemical Co., St. Louis, MO. All other chemicals were of reagent grade. 
Cell Culture. Murine osteoblast-like MC3T3-El cells were provided by Dr. 
Louis Gerstenfeld, Children's Hospital, Boston, MA, and Dr. Renny Franceschi, 
University of Michigan, Ann Arbor. Cells were plated onto 100-mm tissue culture 
dishes in Dulbecco's modified Eagle's medium (DMEM), containing 10% heat-treated 
(56°C, 30 min) newborn bovine serum (NBS) plus 1 % non-essential amino-acid and 
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100 ug/ml of each penicillin and streptomycin. Cultures were maintained at 37°C in a 
fully humidified atmosphere of 5% CO2 in air. Media was changed eveiy three days. 
Cells in the logarithmic growth phase were dissociated with tiypsin/EDTA, counted in 
a hemocytometer, and inoculated at 200,000 cells/plate. At the density of 80%, the 
cells were fed with serum-free media ( + 0.1 % BSA), containing 50 ug/ml of ascorbate 
and lOmM (3-glycerophosphate for 24 hours. Cells were then refed with the same 
media plus or minus TGF-(31, for the appropriate period of time. Experiments were 
performed after no more than 3 passages from one set of frozen cell stocks. 
Assay of Lysyl Oxidase Activity. Lysyl oxidase enzyme activity was measured 
in the conditioned media and cell layers, using recombinant human [3H]-tropoelastin 
substrate (Bedell-Hogan, et al., 1993). Briefly, cells were cultured as described above. 
Media samples (0. 5 ml) were assayed in quadruplicate in a final volume of 1 ml, 
containing 0.1 M borate, 0.15 M NaCl, pH 8.0, and 160,000 cpm of [3H]-tropoelastin 
in the presence and absence of 1 x 10-4 M BAPN. Reactions were incubated for 90 
minutes at 37°C, followed by distillation under vaccum. Radioactivity in 0.5 ml 
aliquots of distillate was determined by liquid scintillation spectrometry. Units of 
enzyme activity were defined as dpm released above the BAPN control. The 
scintillation counting efficiency was 50%. For normalizing the enzyme activity to cell 
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number, media was collected and assayed for lysyl oxidase activity, and cells from the 
same plate were dissociated and counted in a hemocytometer. 
Cell layer lysyl oxidase enzyme activity was measured as follows. The media 
was first removed and cells were washed three times with PBS. One ml of extraction 
buffer (0.02 Mboric acid, 4 Murea, 0.15 MNaCl, pH 8.0) plus 0.001 MPMSF and 
10 µI of aprotinin per 10 ml of extraction buffer was added to the plates. The cells 
were scraped with a rubber policeman and suspended five times with a 21 gauge 
needle and ten times with 18 gauge needle. The suspension was transferred to 
microfuge tubes and spun down at 4 °C for 10 min at full speed The supernatant was 
dialyzed overnight against 0.02 M boric acid, pH 8.0, and 0.5 ml samples were 
assayed in quadruplicate as described above. 
RNA Isolation and Northern Analysis. Total RNA was prepared using Tri-
Reagent™ (Chomczynski, 1993). Ten micrograms of denatured RNA was applied per 
lane and separated by eletrophoresis on 1 % agarose gels, containing 18% 
formaldehyde, and transferred to Gene Screen TM nylon membranes using 10-fold SSC 
as a transfer buffer. Membranes were baked at 80°C for 1 hour and prehybridized at 
42°C for 4 hours in hybridizing solution (50% formamide, 20% SSPE, 10% 5-fold 
Denhardt's solution, 0.2% SDS, 0.05% Na2PPi and 1% ssDNA). Membranes were 
then hybridized for 18 hat 42°C with a [32P]-labeled COLlAl cDNA (Huerre et al., 
33 
1982), [32P]-labeled mouse lysyl oxidase cDNA probe (Kenyon : et al., 1991), or with 
a [32P]-labeled bFGF cDNA probe (Shunichi et al., 1988). For normalization, blots 
were stripped and rehybridized with a radiolabeled 18S ribosomal probe (Hillis & 
Dixon, 1991). 1 x 106 cpm of probe was used per ml of hybridizing solution. Probes 
were labelled using the random primer method (Feinberg & Vogelstein, 1983). The 
membranes were washed twice at 42°C for 30 min each in 2-fold SSC plus 0.1 % SDS 
and once at 50°C, 55°C and 60°C for 1 hour each in 0.2-fold SSC plus 0.1 % SDS. 
Blots were subjected to autoradiography and were developed after 12- to 48-hours 
exposure at -80°C. Autoradiograms were assessed and normalized by densitometric 
scanning. Values for standard error were derived from triplicate scans of films. 
Experiments were performed at least twice. 
Pulse-labeling and Immunopreciptation. Cells were grown to 80% confluence 
and then fed with serum free media ± TGF-J3 l ( 400 pM) for the appropriate period of 
time. Cultures were then refed and incubated for 20 min with 7 ml/plate of serum-free 
and methionine-free DMEM ± TGF-J31 (400 pM). Cultures were then refed with the 
same media± TGF-J31 (400 pM) supplemented with 50 mCi/ml of [35S]methionine 
(1175 Ci/mmol; New England Nuclear, NEG-072). Following incubation, media and 
cell layer were harvested and prepared for immunoprecipitation as described 
previously (Trackman et al., 1992). Constant cpm from the cell layer and media were 
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used for immunoprecipitation with rabbit anti-bovine aortic lysyl oxidase (Trackman 
et al., 1992). A competition reaction was set up, incubating an additional 
immunoprecipitation containing 50 µg of rat lysyl oxidase maltose binding fusion 
protein produced in E.coli (Feres-Filho, et al., 1995). Samples were subjected to SDS-
PAGE, and the gels were treated with Resolution™ (EM Corp., Chestnut Hill, MA). 
After being dried under vacuum, gels were exposed to Kodak XAR-5 film with an 
intensifying screen at-80°C for 5 to 30 days. 
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RESULTS 
Dose-dependent regulation of lysyl oxidase by bFGF. Preconfluent MC3T3-
El cells were cultured in DMEM supplemented with 10% NBS, in the absence 
( control) or presence of different concentrations of bFGF, for 24 hours. A dose-
dependent down-regulation in the steady-state lysyl oxidase and COLlAl mRNA 
levels was found (Figure 1 ). Down-regulation of lysyl oxidase mRNA to about 40% 
of control occurred at 1 nM bFGF. COLlAl was down-regulated to less than 5% of 
control at 1 nM bFGF. Interestingly, at lower concentrations, bFGF caused a modest 
up-regulation in steady-state lysyl oxidase mRNA levels, but not in COLlAl (Figure 
1). The same results were observed culturing the cells in serum-free media 
containing 0.1 % BSA ( data not shown). Experiments were performed at least two 
times, all with similar results. 
Down-regulation of lysyl oxidase by bFGF is time-dependent. The time-
dependent regulation of steady-state lysyl oxidase mRNA levels and enzyme activity 
by 1 nM bFGF was tested Six hours of bFGF-treatment caused a 60% increase in the 
steady-state lysyl oxidase mRNA level, and a 20% increase in enzyme activity (Figure 
2 A and Table I). This was followed by down- regulation of steady-state lysyl oxidase 
mRNA to about 25% of control (75% reduction) which occurred at 24 and 48 hours 
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of treatment. The decreased lysyl oxidase mRNA levels were not accompanied by a 
similar decrease in media enzyme activity (Figure 2 A and Table I). No enzyme 
activity was detected in the cell layer ( data not shown). 
We then tested the notion that accumulation of active enzyme in the cell culture 
medium coupled to slow down-regulation of lysyl oxidase mRNA could account for 
the relatively high lysyl oxidase activity found at 24 hours of bFGF treatment. Cells 
were treated with growth factor, and media was changed after 24 hours. Lysyl oxidase 
enzyme activity was then assayed after an additional 24 and 48 hours of culturing. 
Thus, new enzyme activity produced after the full inhibitmy effect of bFGF was 
measured Changes in steady-state mRNA levels were determined from parallel 
cultures to establish that growth factor-dependent changes were maintained 
throughout the experiment. Lysyl oxidase enzyme activity was also determined in 
cultures without refeeding, to confirm the relatively high enzyme activity found under 
these conditions. 
As shown in Table II, lysyl oxidase enzyme activity in the new media 
decreased to 30% and 20% of controls after 24 and 48 hours, respectively. These 
results agree with the decrease in steady-state lysyl oxidase mRNA levels isolated 
from parallel cultures. As expected, cultures not refed exhibited high enzyme activity 
relative to changes in lysyl oxidase mRNA levels (Table II). bFGF down-regulation of 
lysyl oxidase and COLlAl mRNA levels was maintained throughout the experiment 
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(Figure 2 B). Experiments performed under serum-free conditions yielded similar 
results (data not shown). Thus, bFGF-dependent changes in steady-state lysyl oxidase 
mRNA levels resulted in corresponding changes in lysyl oxidase enzyme activity. 
Analysis of changes in mRNA decay rates. In preparation for analyzing the 
degree of post-transcriptional down-regulation of lysyl oxidase mRNA by bFGF ( see 
below), a detailed time study was performed We wished to establish the time at 
which up-regulation of lysyl oxidase ceased, and down-regulation began. As noted, 
our ultimate objective was to compare the relative bFGF-dependent changes in decay 
rates of COLlAl and lysyl oxidase mRNA's. 
Down-regulation of steady-state lysyl oxidase mRNA levels by 1 nM bFGF 
occurred after 12 hours and reached maximum effect at 24 hours (Figure 3). 
Interestingly, down-regulation of steady-state COLlAl mRNA occurred earlier, to a 
higher degree, and was maintained for at least 48 hours. These results are consistent 
with the dose-response study (Figure 1) where COLlAl was down-regulated at lower 
concentrations of bFGF compared to lysyl oxidase. 
bFGF-dependent changes in lysyl oxidase, collagen, and GAPDH mRNA half-
lives were determined MC3T3-El cells were treated without or with 1 nM bFGF for 
12 hours, and then 20 µg/ml DRB was added to inhibit new mRNA synthesis. 
Cultures were harvested at intervals over the next 12 hours, and RNA was isolated 
Parallel cultures not treated with DRB were grown in order to verify bFGF-dependent 
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changes in steady-state mRNA levels. Total RNA was subjected to Northern blot 
analysis (Figure 4). Lysyl oxidase mRNA decayed with a t112 of 9 hours (r = 0.9386) 
in DRE-treated cells. The t112 for DRB- plus bFGF-treated cells was 6.38 hours (r = 
0.9544), a decrease of 30%. Thus, post-transcriptional mechanisms account for about 
50% of the lysyl oxidase regulation by 1 nM bFGF, as steady-state mRNA levels were 
decreased to 63% of controls. Similar figures were found for COLlAl mRNA (Figure 
4). The control half-life for COLlAl was 6.9 hours (r = 0.9354) and 3.6 hours (r = 
0.9782) for bFGF-treated cultures, accounting for 50% of down-regulation. These 
results are validated by analysis of bFGF regulation of GAPDH mRNA ( control, t112 = 
14.8 hours, r = 0.9845; + bFGF, t112 = 12.9 hours, r = 0.9445r Whereas the bFGF-
treated steady-state mRNA levels for GAPDH increased by 70%, the stability of 
GAPDH mRNA increased by less than 10%. Thus, GAPDH regulation by bFGF was 
found not to be post-transcriptional (Figure 4). 
Effects of cycloheximide. Inhibition of protein synthesis can influence growth 
factor-dependent effects on gene expression by different mechanisms. In cases of 
transcriptional control, cycloheximide may cause loss of labile transcription factors. In 
cases of posttranscriptional control, inhibition of protein synthesis by cycloheximide 
sometimes causes large increases in mRNA levels. This may be due to 
cycloheximide-dependent loss of labile proteins that function to destabilze the mRNA 
(Fuentes & Taylor, 1993), or protection of the mRNA by bound ribosomes (Beelman 
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& Parker, 1995). We therefore wished to establish whether bFGF down-regulation of 
lysyl oxidase was influenced by cycloheximide. 
Treatment of MC3T3-El cells with cycloheximide for the final 8 hours of 20-
hour exposures to 1 nM bFGF resulted in little change in the down-regulation of lysyl 
oxidase, compared to controls without bFGF. In two experiments, bFGF-treated 
cultures had steady-state lysyl oxidase mRNA levels of 37.5% ± 6.5, and 50% ± 5% in 
the presence, and absence of cycloheximide, respectively. COLlAl down-regulation 
by bFGF was also maintained under these conditions (Figure 5). Interestingly, the 
steady-state lysyl oxidase mRNA levels in the control and growth factor treated cells 
were increased by about 2.5-fold by cycloheximide (Figure 5). These results suggest 
that cycloheximide influences the level of constitutive expression of lysyl oxidase 
mRNA in MC3T3-El cells, but not that of COLlAl and GAPDH mRNA's. 
Moreover, new protein synthesis is not required for bFGF-mediated down-regulation 
of steady-state lysyl oxidase mRNA levels. 
Dose-dependent up-regulation of lysyl oxidase by TGF-pl. Preconfluent 
MC3T3-El cells were cultured in serum-free media supplemented with different 
concentrations of TGF-P 1 (0 - 400 pM) for 24 hours. A dose-dependent up-regulation 
in the steady-state lysyl oxidase and COLlAl mRNA levels was found (Figure 6). 
Lysyl oxidase mRNA increased 8.8-fold of control in the presence of 400 pM TGF-
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J31. COLlAl steady-state mRNA levels also increased but reached a modest level of 
3.5-fold of control at 400 pM TGF-J31. Lysyl oxidase enzyme activity in the cell 
culture media was stimulated by 4 and 40 pM TGF-J3 l comparable to increases 
observed in the mRNA levels (Table III). In contrast, 400 pM TGF-J31 caused a 
smaller increase in lysyl oxidase enzyme activity (5.4-fold) compared to the 8.8-fold 
increase in lysyl oxidase steady-state mRNA levels. No enzyme activity was detected 
in the cell layers ( data not shown). These experiments were performed twice yielding 
similar results. 
Time-dependent regulation of lysyl oxidase. The time-dependent regulation 
of steady-state lysyl oxidase mRNA levels and enzyme activity by 400 pM TGF-J3 l
was determined TGF-J3 l increased steady-state lysyl oxidase mRNA levels as early 
as 3 hours of treatment, reaching a maximum at 12 hours (Figure 7 B). Lysyl oxidase 
enzyme activity in the cell culture media was stimulated to a lesser degree, and peaked 
later, at 18 hours (Figure 7 A). The delay between steady-state lysyl oxidase mRNA 
levels and enzyme activity suggests that post-translational mechanisms may limit the 
formation of fully active lysyl oxidase. The following experiments were performed to 
investigate potential limiting steps in the biosynthesis of fully active lysyl oxidase. 
We also tested whether the partial loss of effect seen after 12 hours of TGF-J31-
treatment could be relate to increased expression of bFGF in these cells. As expected, 
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MC3T3-El cells treated with 400 pM TGF-Pl display a time-dependent increase in 
steady-state bFGF mRNA levels begining at 6 hours and peaking at 12 hours (Figure 
10). This result confirm the pleiotropic characteristics of growth factors, in general, 
and in particular the reports that TGF-P I -treatment stimulates the expression of bFGF 
(Hurley et al., 1994). 
Synthesis and Secretion of the Lysyl Oxidase Precursor. We tested whether 
TGF-P 1 increased the synthesis of the lysyl oxidase precursor parallel to changes in 
steady-state lysyl oxidase mRNA Cells were pre-treated with or without 400 pM 
TGF-P 1 for 4 or 15 hours, and then pulse labeled with [35S]methionine for three hours. 
Figure 8 shows autoradiograms of lysyl oxidase immunoprecipitates fr~m the media 
(lanes 1 - 5) and cell layers (lanes 6 - 9) of these cultures. The bands seen in the cell 
layers correspond to the 50 kDa N-glycosylated lysyl oxidase proenzyme (Trackman, 
et al., 1992). TGF-Pl increased the labeled pool oflysyl oxidase precursor in the cell 
layer after 4 hours and 15 hours of growth factor pre-treatment compared to control 
cultures. A 5.5-fold increase in the amount of labeled proenzyme was detected after 15 
hours of growth factor treatment compared to 4 hours of treatment, revealed by 
scanning laser densitometry of autoradiograms. This change was similar to that seen at 
the mRNA level (Figure 7 B), where a 6.9-fold increase in lysyl oxidase steady-state 
mRNA levels occurred between 3 and 12 hours of treatment with TGF-P 1. Thus, as 
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expected, increases in cell layer proenzyme labeling closely parallel changes in lysyl 
oxidase steady-state mRNA Under these conditions of pulse-labeling, no lysyl 
oxidase proenzyme was detected in control cultures not treated with growth factor. 
In contrast, radioactive secreted proenzyme from growth factor-treated cells 
was similar after 15 hours of growth factor treatment compared to 4 hours of 
treatment under these conditions (Figure 8 A). Control media had rto detectable 
proenzyme. No labeled 32 kDa lysyl oxidase was detected under these conditions in 
control or growth factor treated cultures. These findings suggest that synthesis, 
secretion and extracellular proteolytic processing of lysyl oxidase requires more than 
three hours in MC3T3-El cells. 
Accumulation of media lysyl oxidase proenzyme in TGF-Pl-stimulated 
cultures. We next tested whether proteolytic processing may be insufficient to 
efficiently convert the lysyl oxidase proenzyme secreted from TGF-J3 l -stimulated 
cells. In this experiment, cells were treated with or without 400 pM TGF-J3 l in the 
presence of radioactive methionine continuously for 12 hours and 18 hours. Media 
and cell layers were immunoprecipitated with lysyl oxidase antibodies. This 
experiment was designed to reveal the molecular forms of lysyl oxidase that 
accumulate in control and growth-factor treated cell cultures over relatively long 
periods of pulse-labeling. 
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As shown in Figure 9 (lanes 1 - 4 ), TGF-P 1 increased the pool of lysyl oxidase 
precursor in the conditioned media in a time-dependent manner. Similarly, there was a 
greater amount of labeled 32 kDa lysyl oxidase at 18 hours compared to 12 hours. 
This is consistent with increased enzyme activity observed after 18 hours of growth 
factor treatment (Figure 7). Densitometric laser scanning of autoradiograms showed 
comparable time-dependent increases in the 50 kDa precursor (12 h, 689 ± 5.6; 18 h, 
1,964 ± 25.5) and in the 32 kDa form oflysyl oxidase (12 h, 378 ± 33.2; 18 h, 1,121 
± 29.7), in TGF-Pl-treated cells. These results demonstrate approximately a 3-fold 
time-dependent increase in both the 32 kDa and 50 kDa forms oflysyl oxidase in cells 
treated with growth factor for 12 hours compared to 18 hours. The accumula!ion of 50 
kDa lysyl oxidase in the media suggests that the conversion to the 3 2 kDa species was 
limited by extracellular proteolytic activity. 
Scanning laser densitometiy of autoradiograms shown in Figure 9 revealed that 
the level of labeled 32 kDa lysyl oxidase was stimulated by 13- and 20-fold in TGF-
P 1-treated cells compared to unstimulated cells at 12 and 18 hours, respectively. 
Assuming that the 32 kDa molecular form of lysyl oxidase was fully active and that 
the specific radioactivity of methionine pools was comparable in all cultures, this 
would predict a degree of stimulation of lysyl oxidase enzyme activity by TGF-P 1 of 
10- to 20-fold compared to unstimulated control cultures. Interestingly, we observed at 
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most a 6-fold stimulation of enzyme activity at 18 - 24 hours (Table III). We conclude 
that lysyl oxidase is unlikely to be fully active in TGF-131 stimulated cultures ( see 
Discussion). 
Results obtained from the cell layer suggest that significant accumulation of the 
lysyl oxidase proenzyme did not occur. Moreover, absence of the 32 kDa molecular 
form in the cell layer is consistent with the absence of enzyme activity in this fraction. 
Thus in these osteoblastic MC3T3-El cell cultures, lysyl oxidase was synthesized as a 
50 kDa precursor (Figure 8), secreted and processed proteolytically to a 32 kDa 
molecular species that remained soluble (Figure 9). This is distinct from studies in 
neonatal rat aorta smooth muscle cells, and rat lung fibroblasts, where lysyl oxidase 
enzyme activity and the 32 kDa molecular form were shown to accumulate in the cell 




Regulation of lysyl oxidase and type I collagen by bFGF 
The results presented show that lysyl oxidase expression is regulated by 
bFGF in osteoblastic MC3T3-El cells. Steady-state lysyl oxidase mRNA levels 
decreased after 24 hours of 1 and 10 nM bFGF treatment, similar to changes found 
in COLlAl mRNA. Lowered lysyl oxidase mRNA levels resulted in diminished 
production of new lysyl oxidase enzyme activity. 
In contrast, 0.01 - 0.1 nM bFGF caused an increase in lysyl oxidase mRNA 
levels, but not in COLlAl mRNA. Short-term treatment of MC3T3-El cells for 6 
hours with 1 nM bFGF caused increased steady-state levels of both COLlAl and lysyl 
oxidase mRNA' s. This short-term treatment caused a corresponding increase in the 
culture media lysyl oxidase enzyme activity. 
These time- and dose-dependent effects of bFGF on lysyl oxidase and 
COLlAl gene expression may be related to time-dependent effects of bFGF on 
collagen synthesis observed in fetal rat calvaria organ cultures (Canalis et al., 1988; 
Hurley et al., 1992; McCarthy et al., 1989). In these studies, treatment of organ 
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cultures with bFGF for 24 hours resulted in lowered collagen synthesis. In contrast, 
treatment with bFGF for 24 hours followed by culturing in the absence of growth 
factor for an additional 24 or 48 hours resulted in increased collagen synthesis. The 
stimulat01y effects on collagen synthesis were principally due to the mitogenic effect 
of bFGF on osteoblasts in the organ cultures (Canalis et al., 1988), though direct 
effects on collagen gene expression were not excluded Similarly, in vivo studies of 
chick embiyos treated with bFGF resulted in decreased osteogenesis in the short-term. 
It was suggested that in addition to increasing the numbers of osteogenic cells, bFGF 
treatment might also increase the osteogenic potential of osteoblastic cells after bFGF 
application was discontinued compared to embiyos not treated with bFGF (Frenkel et 
al., 1992). Time-dependent effects on lysyl oxidase and collagen gene expression 
could be physiologically important, since exposure of osteoblasts to bFGF in vivo 
resulting from injuiy is likely to be acute. A more complete understanding of the 
effects of bFGF on bone formation will require vatying the duration of bFGF exposure 
of osteoblatic cells and determining the subsequent changes in cell number, lysyl 
oxidase synthesis, activation, and turnover, collagen synthesis and deposition, and 
ultimately mineralization in vitro. 
The observed bFGF-dependent increase in steady-state GAPDH mRNA levels 
is probably related to changes in the proliferative state of MC3T3-El cells. In 
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agreement with this concept, Meyer-Siegler and coworkers have found that the 
expression of the GAPDH gene was dependent on the proliferative state of several 
human cell lines (Meyer-Siegler et al., 1992). A growth-dependent increase in 
GAPDH gene expression was documented Mitogenic effects of bFGF on MC3T3-El 
are well established (Hurley et al., 1992). bFGF influences differentiation of 
osteoblasts by inhibiting the expression of osteoblastic markers, including alkaline 
phosphatase and type I collagen (McCarthy et al., 1989). FGF also induces the 
expression of collagenase and plasminogen activator, leading to matrix degradation 
(Gross et al., 1988). Thus, the down-regulation of lysyl oxidase expression by bFGF 
is consistent with induction of a proliferative, matrix-resorbing phenotype. 
The time-dependent down-regulation oflysyl oxidase mRNA by 1 nM bFGF is 
quantitatively less than that of COLlAl mRNA This may indicate that minimum 
expression of lysyl oxidase is required by these cells. It is of interest that lysyl oxidase 
has been shown to be encoded by the rrg, a putative anti-oncogene (Kenyon: et al., 
1991) . Besides its well known function in collagen and elastin crosslinking, lysyl 
oxidase expression is necessary for the maintenance of the normal phenotype in NIH 
3T3 fibroblasts (Contente et al., 1990). 
Post-transcriptional control of gene expression has been demonstrated for 
several extracellular matrix genes including elastin (Pierce et al., 1992) and COLlAl 
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(Dhawan et al., 1991). Transcript stability is believed to be regulated principally by 
sequences located in the 5' - and 3 '-untranslated regions and the length of the 
polyadenyl-tail (Beelman & Parker, 1995). It is of interest that a conserved sequence 
has been identified in the 3 '-untranslated region of COL lAl that appears to mediate 
posttranscriptional regulation by dexamethasone (Maatta & Penttinen, 1993; Maatta & 
Penttinen, 1994 ). Due to the presence of large 5' - and 3 ' - untranslated regions in lysyl 
oxidase, we wished to establish the degree of post-transcriptional mechanisms in the 
bFGF-mediated effects. Our analyses indicate that post-transcriptional mechanisms 
were responsible for 50% of lysyl oxidase and COLlAl mRNA regulation by bFGF. 
The remaining 50% of down-regulation of lysyl oxidase by bFGF is likely to be 
transcriptional, as has been shown for COLlAl (Hurley et al., 1993). Comparison of 
the complete 3.5 kb of rat 3'-untranslated region of lysyl oxidase (Trackman et al., 
1995) to that of human (Boyd et al., 1995) reveals sequence conservation with an 
identity of 72.6% (not shown). It will be of interest to establish whether conserved 
regions of the 3 'untranslated region of lysyl oxidase mRNA confers stability in 
response to growth factors and cytokines. 
We employed cycloheximide to test whether labile protein factors might be 
necessary for the bFGF-mediated effect on lysyl oxidase and COLlAl expression 
Cycloheximide caused increased levels of lysyl oxidase messages, but no changes 
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were found in COLlAl and GAPDH mRNA's. Further, labile bFGF-induced protein 
factors appear not to mediate down-regulation of COLlAl and lysyl oxidase mRNA 
levels. This effect indicates that the constitutive expression of lysyl oxidase mRNA is 
influenced by labile factors in MC3T3-El cells. As unstable proteins appear not to 
directly mediate bFGF-dependent regulation of lysyl oxidase, we speculate that 
activation of stable protein factors by posttranslational modification such as 
phosphorylation/dephosphmylation pathways may result in bFGF-dependent down-
regulation of lysyl oxidase steady-state mRNA levels. 
These discussed effects of bFGF, a mitogenic growth factor, and TGF-J31 (see 
below), a differentiation factor, on lysyl oxidase suggest its importance, either directly 
or indirectly, in maintaining an equilibrium between cell proliferation and 
differentiation. 
Regulating effects of TGF-J31 
TGF-J3 l is present in high amounts in bone (Seyedin et al., 1985), and has 
been shown to stimulate the synthesis of type I collagen, fibronectin and proteoglycans 
by osteoblastic cells (Shibata et al., 1993; Takeuchi et al., 1995). Type I collagen 
synthesis and deposition have been shown to be uncoupled processes in developing 
MC3T3-El cells (Quarles et al., 1992). Moreover, TGF-J31-stimulated collagen 
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accumulation in cell layers of rat calvaria osteoblastic was found to be partially 
controlled by unidentified post-translational mechanisms (Centrella et al., 1992). 
Recently, lysyl oxidase was implicated in regulating collagen fibrillogenesis in chick 
osteoblasts (Gerstenfeld et al., 1993). In addition, lysyl oxidase mRNA was found to 
increase eightfold in MC3T3-El cells treated with TGF-f31 (Shibanuma_. et al., 1993). 
In the present study, we investigated the idea that lysyl oxidase might be a 
major target for TGF-f31 in MC3T3-El osteoblastic cultures. We now report that 
TGF-f31 increased steady-state lysyl oxidase mRNA levels and lysyl oxidase 
proenzyme in a dose- and time-dependent manner. 
The time-dependent increase in steady-state lysyl oxidase mRNA was 
maximum at 12 hours of TGF-f31 treatment, and was followed by diminished up-
regulation. The regulation of steady-state COLlAl mRNA was comparatively less 
complex. The maximum increase occurred similarly at 12 hours but, unlike lysyl 
oxidase, it was of small magnitude and remained constant thereafter (Figure 7 B). 
These results may indicate a critical role for lysyl oxidase in regulating collagen 
insolubilization and cross-linking in osteoblastic cultures. 
Our data showing that bFGF down-regulates COLlAl and lysyl oxidase 
mRNA' s, together with the complex TGF-f31-mediated regulation of lysyl oxidase, 
prompted us to verify the known effect of TGF-f31 treatment in increasing the 
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expression of bFGF (Hurley, et al., 1994 ). Our finding that TGF-P 1 increases the 
steady-state bFGF mRNA levels in MC3T3-El cells at 6 and 12 hours suggests that 
increased bFGF caused by TGF-P 1 may down-regulate lysyl oxidase. This requires 
further investigation before a cause-effect conclusion can be draw. One way to address 
this question would be the stable transfection of these cells with sense and antisense 
bFGF cDNA expression vectors (Redekop & Naus, 1995). The subsequent analysis of 
lysyl oxidase in these cells treated with TGF-P 1 would elucidate the role of bFGF in 
lysyl oxidase regulation. 
Increases in lysyl oxidase mRNA by 400 pM TGF-P 1 were followed to a lesser 
degree by increases in enzyme activity. Moreover, we found a 6-hour time delay 
between the growth factor-stimulated maximum effect on lysyl oxidase message and 
enzyme activity. This suggests that lysyl oxidase biosynthesis is slow, and may be 
limited by posttranslational steps in osteoblastic MC3T3-El cells. Unpublished results 
from our laboratmy show that TGF-P 1 also increases the extracellular proteolytic 
processing of lysyl oxidase proenzyme in a dose- and time-dependent (F eres-Filho et 
al., 1995). 
This notion was further supported by immunopreciptation experiments after a 
3-hour (short term) pulse-labeling, where the resulting labeled lysyl oxidase 
proenzyme was predominantly associated with the cell layer (intracellular). Labeled 
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lysyl oxidase proenzyme increased in proportion to TGF-J3 l-dependent changes in 
steady-state lysyl oxidase mRNA levels, indicating that there was no block of 
translation of lysyl oxidase pro-protein in TGF-J3 l-stimulated cells. Experiments with 
long periods of continuous pulse-labeling displayed increased bands corresponding to 
both 50 kDa precursor and 32 kDa mature enzyme in the conditioned media 
Accumulation of increased levels of the 50 kDa molecular species in the media and not 
in the cell layer from long-term pulse labeling experiments suggested that lysyl 
oxidase processing protease(s) partially limited production of the 32 kDa molecular 
form of lysyl oxidase . It is noteworthy that in other cell systems TGF-J3 l has been 
shown to inhibit the expression of proteases (Laiho . et al., 1986; Lund.. et al., 1987), 
and to induce expression of protease inhibitors (Edwards et al., 1987; Laiho et al., 
1986). 
As noted, 400 pM TGF-J3 l caused an increase in steady-state lysyl oxidase 
mRNA and in both the 32 kDa and 50 kDa lysyl oxidase protein molecules, although 
enzyme activity increased to a lesser extent. These findin~ may be related to previous 
studies where a catalytically inactive 32 kDa form of lysyl oxidase was isolated from 
bovine aorta (Sullivan & Kagan, 1982), and to the observation indicating that purified 
lysyl oxidase is not fully active (Williamson et al., 1986). Furthermore, TGF-J31 
treatment might not have increased the levels of proteins involved in copper transport 
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and metabolism, which could also have impaired development of full lysyl oxidase 
enzyme activity (Fife et al., 1994; Yamada et al., 1993). Analysis of active lysyl 
oxidase purified from control- and TGF-P I-treated MC3T3-El cultures for metal, 
organic cofactor, and proportion of functional active sites would further define the 
posttranslational modifications which are required for full activation oflysyl oxidase. 
It is known that the 32 kDa molecular form oflysyl oxidase is active, as this is 
the form of the active enzyme commonly isolated from connective tissues (Kagan, 
1986). Similarly, a 45 kDa form of rat lysyl oxidase has been shown to be active 
(Romero-Chapman et al., 1991 ). It is unknown whether the 50 kDa molecule secreted 
by cultured cells is active. Indirect evidence to date suggests that the 50 kDa molecule 
is catalytically inactive. Normal cell cultures exhibiting lysyl oxidase activity in the 
cell layer such as neonatal rat aorta smooth muscle cells and rat lung fibroblasts have 
been shown to accumulate a 32 kDa form of lysyl oxidase (Boak et al., 1994; 
Trackman et al., 1992). In contrast, cultures such as the MC3T3 El cells grown as 
described in the present study accumulate no 32 kDa lysyl oxidase in the cell layer, 
and exhibit no detectable activity in this fraction. All activity was found in the 
medium. Thus, lysyl oxidase activity correlates well with the 32 kDa molecular form 
of lysyl oxidase, and not with the 50 kDa molecular form. Interestingly, c-H-ras 
transformed NIH 3 T3 cells transfected with a lysyl oxidase expression vector 
produced 50 kDa lysyl oxidase, and little or no 32 kDa form, and exhibited no 
54 
detectable enzyme activity (Trackman. et al., 1992). As noted above, however, lysyl 
oxidase undergoes multiple posttranslational modifications including organic and 
inorganic cofactor constitution. These processes may also have been impaired in these 
ras-transfonned cells. As MC3T3-El cells are phenotypically normal and produce 
high levels of soluble lysyl oxidase enzyme activity, they may provide a suitable 
model to more fully address these questions. 
MC3T3-El cells have been shown to undergo all phases of osteoblastic 
differentiation, resulting in the production of a mineralized extracellular matrix 
(Quarles et al., 1992). In view of the results now obtained in this cell culture model, 
showing that lysyl oxidase activity and mRNA levels are significantly regulated by 
bFGF and TGF-P 1, it will be of interest to further these studies in a long term, 
mineralizing organ and cell cultures. These studies should add evidence to the 
physiological importance of lysyl oxidase in the synthesis and deposition of a 
collagenous bone matrix controlled by different factors. 
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SUMMARY AND CONCLUSIONS 
The goals of this thesis project were to determine whether lysyl oxidase, like its 
type I collagen substrate, is regulated by bFGF and TGF-P 1 in osteoblastic MC3T3-
El cells. The results obtained in this study indicate that lysyl oxidase, activity and 
mRNA, is down-regulated by bFGF in a dose- and time-dependent manner. This 
regulation is similar, but lower than that of steady-state COLlAl mRNA. Moreover, 
these regulations are mediated partially by post-transcriptional mechanisms. On the 
other hand, TGF-J3 l increases the levels of steady-state lysyl oxidase mRNA, 
proenzyme synthesis and secretion, and enzyme activity in a dose- and time-dependent 
manner. A discrepancy between the synthesis of lysyl oxidase proenzyme and enzyme 
activity indicates that the extracellular maturation of lysyl oxidase is limited by 
posttranslational steps in these MC3T3-El cells. Furthermore, the TGF-J31-mediated 
effects on steady-state lysyl oxidase mRNA levels are greater than the effects on 
steady-state COLlAl mRNA levels, indicating that lysyl oxidase is a major target for 
TGF-J3 l in this cell culture model. Taken together these results suggest that lysyl 
oxidase might be important in bone biology. 
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Figure 1. Down-regulation of lysyl oxidase and COLlAl steady-state mRNA levels by bFGF is dose-
dependent. MC3T3-El cells were cultured in media containing 10% NBS in the absence (control) or presence of 
different concentrations of bFGF (0.01, 0.1, 1 & 10 nM). After 24 hours, total RNA was extracted, separated by 
eletrophoresis and blotted to nylon membranes as described in Materials and Methods. Inset, Autoradiogram of 
Northern Blots probed with [32P]-radiolabeled COL lAl and .lysyl oxidase cDNA' s, and with DNA for 18 S 
ribosomal RNA (18S rRNA) . Lane 1, control; lane 2, 0.01 nM bFGF; lane 3, 0.1 nM bFGF; lane 4, 1 nM bFGF ; 
lane 5, 10 nM bFGF. Signals were quantitated by scanning laser densitometty and signals for lysyl oxidase and 
collagen were normalized to the signals for 18S rRNA. Values represent mean± SD. Hatched bars, lysyl oxidase; 















Figure 2. Time-dependent effect of 1 nM bFGF on the steady-state levels of 
COLlAl and lysyl oxidase mRNA's. Autoradiogram of Northern blot of total RNA 
(10 ug/lane) from MC3T3-El cells cultured in the absence (control) or presence of 
bFGF. A. Lane 1, control (6 hr); lane 2, bFGF (6 hr); lane 3, control (24 hr); lane 4, 
bFGF (24 hr); lane 5, control (48 hr); lane 6, bFGF (48 hr). B. Media was changed 
(refed) at 24 hours and cells were cultured for additional 48 hours. Lane 1, control (24 
hr); lane 2, bFGF (24 hr); lane 3, control (48 hr); lane 4, bFGF (48 hr); lane 5, control 
(48 hr, refed); lane 6, bFGF (48 hr, refed); lane 7, control (72 hr , refed); lane 8, 
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Figure 3. Detailed time-dependent regulation of COLlAl and lysyl oxidase steady-
state mRNA levels by 1 nM bFGF. Hatched bars, lysyl oxidase; and black bars, 
COLlAl . Data are from two experiments. 
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Figure 4. Determination of bFGF Post-transcriptional Regulation of Lysyl 
Oxidase, COLlAl and GAPDH mRNA's by Northern Blotting (A - C); and 
Calculation of Changes in mRNA Half-lives (D -F). A - C: Subconfluent 
MC3T3-El cells were treated with lnM bFGF for 12 hours, and then with 20 
ug/ml of DRB as described in "Materials and Methods". In addition, parallel 
cultures not treated with DRB were grown in order to establish bFGF-dependent 
changes in steady-state mRNA levels. All blots were probed with radiolabeled 
cDNA's for lysyl oxidase, COLlAl, and GAPDH and with a probe for 18S 
ribosomal RNA. A, Northern blots from bFGF- and DRB-treated cells; B, 
Northern blots from DRB-treated cells; and C, blots to establish steady-state 
mRNA changes. For A and B, treatment times refer to hours after DRB addition: 
Lane 1 ( 0 hr); lane 2 (2 hr); lane 3 (4 hr); lane 4 (6 hr); lane 5 (8 hr); lane 6 (10 
hr); lane 7 (12 hr). In C, no DRB was added, but treatment times also refer to time 
after DRB addition, corresponding to A and B: Lanes 1 and 2, (0 hr); lanes 3 and 
4 (6 hr); lanes 5 and 6 (12 hr). Odd numbered lanes; cells not treated with bFGF; 
even numbered lanes, cells treated with 1 nM bFGF. D - F: The hybridization 
signals seen in blots A, B, and C were quantified and normalized to the 18S 
ribosomal RNA signal after densitometric scanning. The resulting data from A and 
B were subjected to linear regression analysis of semi-log plots of the percentage 
of mRNA remaining vs. time, yielding the following decay half-lives: D, lysyl 
80 
of mRNA remaining vs. time, yielding the following decay half-lives: D, lysyl 
oxidase mRNA decayed with a t112 of 9 hours, and 6.38 hours in DRB-(•), and in 
DRB- plus bFGF (□)-treated cells, respectively; E, COLlAl mRNA decayed with 
a tl/2 of 6. 9 hours, and 3. 6 hours in DRB-( • ), and in DRB- plus bFGF-treated 
cells(□), respectively; F, GAPDH decayed with a t112 of 12.8 hours and 13.5 hours 
in DRB- ( •) and in bFGF plus DRB- (□) treated cells, respectively. Correlation 
coefficients (r) for the regression lines ranged from 0.935 to 0.984. The amount of 
regulation accounted for by post-transcriptional mechanisms was calculated 
dividing the bFGF-dependent change in decay half-life for each transcript by the 
change in steady-state mRNA isolated from parallel experiment: lysyl oxidase 
(30% I 63% = 50%); COLlAl (52% / 95% = 54%); GAPDH (5% / 70% = 7%). 











Figure 5. Effect of cycloheximide on lysyl oxidase, COLlAl, and GAPDH mRNA levels. MC3T3-El cells were 
preincubated without (control) or with 1 nM bFGF for 12 hours, and then treated with or without 5 mg/ml 
cycloheximide. After 8 hours, total RNA was isolated and Northern blot analysis was performed Lane 1, control; 
lane 2, bFGF; lane 3, control plus cycloheximide; lane 4, bFGF plus cycloheximide. This experiment was 
performed twice with similar results. 
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Figure 6. Up-regulation of lysyl oxidase and COLlAl steady-state mRNA levels by TGF-J31 is dose-
dependent MC3T3-El cells were cultured in serum-free media containing 0.1 % BSA in the absence ( control) 
or presence of different concentrations of TGF-f31 (4, 40 & 400 pM). After 24 hours, total RNA was 
extracted, separated by electrophoresis and blotted to nylon membranes as described in Materials and 
Methods. Inset, autoradiograms of Northern blots probed with [32P]-radiolabeled lysyl oxidase and COLlAl 
cDNA's, and with DNA for 18S ribosomal RNA (18S rRNA). Lane 1, 0 TGF-f31; lane 2, 4 pM TGF-f31; lane 
3, 40 pM TGF-f31; lane 4, 400 pM TGF-f31. Signals were quantitated by scanning laser densitometry and 
signals were normalized to the signal for 18S rRNA. Black bars, lysyl oxidase; hatched bars, COLlAl. Values 
represent mean± SD obtained from three scanning laser densitomentry determinations from one representative 
experiment. 
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Figure 7. Time-dependent effect of 400 pM TGF-J3 l on lysyl oxidase enzyme 
activity (A); and steady-state levels of lysyl oxidase and COLlAl mRNA's (B). 
A. Lysyl oxidase was measured in the conditioned media, using recombinant 
human [3H]-tropoelastin substrate (see Materials and Methods) . Units of enzyme 
activity were defined as dpm released above the BAPN control. Values are mean 
± SEM of samples assayed in quadruplicate and normalized to 106 cells. Data are 
from one of two replicate experiments. B.Autoradiograms of Northern blots of 
total RNA (10 ug/lane) from MC3T3-El cells cultured in the absence (control) or 
presence of 400 pM TGF-f31. Lane 1, control (3 hr); lane 2, TGF-f31 (3 hr); lane 3, 
control (6 hr); lane 4, TGF-f31 (6 hr); lane 5, control (12 hr); lane 6, TGF-f3 l (12 
hr); lane 7, control (18 hr); lane 8, TGF-f31 (18 hr); lane 9, control (21 hr); lane 
10, TGF-f31 (21 hr); lane 11, control (24 hr); lane 12, TGF-f31 (24 hr). 
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Figure 8. TGF-JH increases the levels of short-term labeled lysyl oxidase proenzyme. MC3T3-El cells 
were pre-treated without ( control) or with 400 pM TGF-P 1 for 4 or 15 hours, and then pulse-labeled with 
[35S]methionine for 3 hours. Radioactive media (7 x 106 cpm) and cell layer (2 x 107 cpm) were 
immunopreciptated with anti-lysyl oxidase antibody as described in Materials and Methods. Samples were 
subjected to SDS-PAGE, and then transfered to PVDF membranes. Autoradiograms of immunopreciptates 
froi;n media: lane 1, control (4 hr); lane 2, TGF-Pl (4 hr); lane 3, control (15 hr); lane 4, TGF-J31 (15 hr); lane 
5, competition. Immunopreciptates from the cell layer: lane 6, control (4 hr); lane 7, TGF-J31 (4 hr); lane 8, 
control (15 hr); lane 9, TGF-J31(15 hr). 









Figure 9. TGF-131 increases the levels of long-term labeled lysyl oxidase proteins. MC3T3-El cells were 
treated without (control) or with 400 pM TGF-131 in the presence of [35S]methionine continuously for 12 and 
18 hours. Radioactive media (3 x 107 cpm) and cell layer (1 x 108 cpm) were immunopreciptated with anti-
lysyl oxidase antibody (see Materials and Methods). Samples were subjected to SDS-PAGE. Autoradiograms 
of immunopreciptates from the media: lane 1, control (12 hr); lane 2, TGF-131 (12 hr); lane 3, control (18 hr); 
lane 4, TGF-131 (18 hr). Immunopreciptates from the cell layers: lane 5, control (12 hr); lane 6, TGF-131 (12 
hr); lane 7, control (18 hr); lane 8, TGF-131 (18 hr) . 




Figure 10. Up-regulation of steady-state bFGF mRNA levels by 400 pM TGF-J31. Autoradiograms of 
Northern blot of total RNA (10 ug/lane) from MC3T3-El cells cultured in the absence (control) or presence of 
400 pM TGF-J3 l, and probed with [32P]-radiolabeled bFGF cDNA. Lane 1, control (3 hr); lane 2, TGF-J3 l (3 
hr); lane 3, control (6 hr); lane 4, TGF-J3 l (6 hr); lane 5, control (12 hr); lane 6, TGF-J3 l (12 hr); lane 7, 
control (24 hr); lane 8, TGF-J31 (24 hr); lane 9, control (48 hr); lane 10, TGF-J31 (48 hr). 
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TABLE I. Normalized lysyl oxidase enzyme activity and steady-state mRNA 
levels from MC3T3-El cells treated without (~gn~-2!2 or with 1 nM bFGF 
b b 
Lysyl Oxi- COLlAl 
a a % of <lase mRNA mRNA (% 
Control bFGF Control (% of Control) of Control) 
6 hours 2,850 ± 802 3,468 ± 629 
24 hours 7,534 ± 1,284 6,450 ± 180 
48 hours 5,215 ± 1,450 4,245 ± 97 
a 
121 ± 34 160 ± 15 
85 ± 14 
81 ± 21 
12 ± 2.5 
48 ± 11 
156 ± 7 
10 ± 1.5 
3 ± 0.2 
Values are mean ± SEM for samples assayed in quadruplicate and normalized to 
106 cells. Data are from one of two replicate experiments. 
b 
% changes are based on mean± SD of values obtained from laser densitometric 
scanning of films developed after different exposure times to radio labeled N orthem 
blots. Data are from one of two replicate experiments . 
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TABLE II. Effect of refeeding on normalized lysyl oxidase enzyme activity 
and steady-state mRNA levels from MC3 T3-E 1 cells treated 
without { control) or with 1 nM bFGF 
b 
Lysyl Oxi-
a a %of <lase mRNA Ratio of 
Control bFGF Control (% of Control) Changes 
(A) (B) (A)+ (B) 
24 hours 5,211 ± 79.4 2,502 ± 266 47 ± 4.8 27 ± 1 1.7 
48 hours 1,897 ± 175 1,033 ± 278 54 ± 14 33 ±4 1.6 
48 hours 2,092 ± 507 633 ± 184 30 ± 8 25 ± 6 1.2 
(refed) 
72 hours 4,227 ± 314 951 ± 135 22 ± 3.2 23 ± 7 0.9 
(refed2 
a 
Values are mean ± SEM for samples assayed in quadruplicate and normalized 
to 106 cells. Data are from one of two replicate experiments. 
b 
% changes are based on mean ± SD of values obtained from laser densitometric 
scanning of films developed after different exposure times to radiolabeled Northern 
blots. Data are from one of two replicate ·experiments . 
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TABLE III. Changes in Normalized Lysyl Oxidase Enzyme Activity and Steady-State 




TGF-J3 40 pM 
TGF-J3 400 pM 
a 




( dpm per 106 cells) 
8,914 ± 830 
13,678 ± 2,732 
32,704 ± 3,230 
















Values are mean ± SEM for samples assayed in quadruplicate and normalized to 106 cells. 
Data are from one of two replicate experiments. 
C 
Data are from Figure 6. 
